Skip to main content


Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

  • Gemma Bruera1, 2,
  • Katia Cannita1,
  • Daniela Di Giacomo2,
  • Aude Lamy3,
  • Thierry Frébourg4,
  • Jean Christophe Sabourin5,
  • Mario Tosi4,
  • Edoardo Alesse2,
  • Corrado Ficorella1, 2 and
  • Enrico Ricevuto1, 2Email author
BMC Medicine201311:59

DOI: 10.1186/1741-7015-11-59

Received: 29 September 2012

Accepted: 4 March 2013

Published: 4 March 2013

Authors’ Affiliations

Medical Oncology, S. Salvatore Hospital, University of L'Aquila
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila
Laboratory of Tumor Genetics, University Hospital
INSERM U614, University of Rouen
Department of Pathology, INSERM U614, Rouen University Hospital